

## PHARMING PROVIDES UPDATE ON OUTSTANDING SHARES

**Leiden, The Netherlands, June 29, 2010.** Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) today announced that its current number of outstanding shares has increased from 285,691,836 at June 18, 2010 to 304,953,323 as per today.

The increase reflects an aggregate number of 7,661,250 shares in relation to conversions of bonds and 11,600,237 shares in relation to the exercise of warrants issued upon entering into €7.5 million private bonds in January 2010. As a result, the original nominal value of the bonds issued in the amount of €7.5 million has decreased to €1.1 million today.

### **About Pharming Group NV**

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. On June 24, the European Medicines Agency adopted a positive opinion for Ruconest(Rhucin)for the treatment of angioedema attacks. Market Authorization in the European Economic Area is therefore expected to be granted in September 2010. The product is also under development for follow-on indications, i.e. antibody-mediated rejection (AMR) and delayed graft function (DGF) following kidney transplantation. Prodarsan® - a product under development by Pharming's subsidiary DNage - is in early stage clinical development for Cockayne Syndrome and lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Recently the partial spin off of DNage was initiated. Additional information is available on the Pharming website, <http://www.pharming.com>.

*This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.*

---

### **Contact:**

Ms. Marjolein van Helmond, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54